We're delighted to announce the release of our 2023 Corporate Responsibility Report: Action for a Healthier Future. We're proud to highlight our progress and unveil our new corporate responsibility strategic pillars & actionable goals. More: ir.ionispharma.com/news-releases/…

We’re pleased to present positive results from our Phase 3 Balance study at the American College of Cardiology Annual Meeting, published in NEJM, for our independent, investigational medicine for patients with FCS.

Read more: bit.ly/3PRWPtT $IONS #ACC24 American College of Cardiology

Looking forward to presenting new data supporting our investigational medicine for familial chylomicronemia syndrome (FCS), a rare, life-threatening disease with no U.S. FDA-approved therapies, at the American College of Cardiology Annual Meeting.

Read More: ir.ionispharma.com/news-releases/… $IONS #ACC24

We’re pleased to announce positive topline results from the Phase 2 study of our investigational treatment for metabolic dysfunction-associated steatohepatitis ( #MASH ), previously referred to as nonalcoholic steatohepatitis ( #NASH ).

Learn more: ir.ionispharma.com/news-releases/…

We are excited to welcome back Kyle Jenne to our executive leadership team in the role of chief global product strategy officer, further strengthening our commercial prowess as a fully integrated biotech company.

Learn more: ir.ionispharma.com/news-releases/…

Today, we announced the appointment of Kyle Jenne as chief global product strategy officer to spearhead the next phase of commercial growth for Ionis.

Learn more: ir.ionispharma.com/news-releases/…

Today we reported 2023 fourth quarter and full year financial results. Read more about our updates and tune in live to the webcast today at 11:30 AM ET to hear from our leadership: ir.ionispharma.com/news-releases/… $IONS

The U.S. FDA has granted Orphan Drug designation to our investigational medicine for the treatment of familial chylomicronemia syndrome, a rare genetic disease characterized by extremely elevated triglyceride levels and acute pancreatitis. Read more: ow.ly/wnV350QBM5K $IONS

The U.S. FDA has granted Fast Track designation to our investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy in adults. Learn more about this news: ow.ly/FJ5z50Qz8cj #RareDisease

Save the date for our Q4 2023 earnings webcast. Register now and tune in live on February 21 at 11:30 AM ET: ow.ly/45Ij50QyIK8 $IONS

Based on the Phase 3 OASIS-HAE data announced earlier today, Ionis is preparing to submit an NDA for donidalorsen. We are grateful to the patients, caregivers, investigators and study teams who participated in this study.

Learn more: ow.ly/tJEb50Qt2PO

Today we are pleased to announce positive topline results from our Phase 3 OASIS-HAE study of donidalorsen, an investigational RNA-targeted prophylactic medicine in development for the treatment of hereditary angioedema (HAE).

Read more: ow.ly/6M8f50Qt2yX

Tune in today for a business update presented by our CEO Brett P. Monia, Ph.D., discussing our significant progress in 2023 and what’s ahead in 2024! Learn more: ow.ly/e42g50QpzQ4 $IONS #JPM2024

We’re excited to be at the 42nd Annual J.P. Morgan
Healthcare Conference, discussing the latest advances and innovations across the healthcare industry! Stay tuned for more to come from #JPM2024 , including updates from our CEO Brett P. Monia, Ph.D.. Learn more: ow.ly/TTKK50QoJoA $IONS

Ionis is proud to have discovered and, in partnership with AstraZenecaUS, developed a new treatment for adults living with polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Learn more about this news: ow.ly/ntA250QltBI $IONS

The U.S. FDA has approved a new treatment for adults living with polyneuropathy of hereditary transthyretin-mediated amyloidosis. Learn more about this news: ir.ionispharma.com/news-releases/… #RareDisease

Today, we shared positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a trial of ION582, an investigational treatment for Angelman syndrome. Updates were presented at the Foundation for Angelman Syndrome Therapeutics Summit.

Learn more: ow.ly/jUE450Q6FBo

New data from the Phase 2 open-label extension (OLE) study of donidalorsen, an investigational treatment for hereditary angioedema, were presented at #ACAAI2023 .

Learn more about this news: ow.ly/sx0950Q63k6

#ICYMI : we announced our Q3 2023 financial updates yesterday. Watch the webcast replay to hear from our leadership: ow.ly/6zRw50Q2NqZ $IONS

Today we reported third quarter 2023 financial results. Read more about our updates and tune in live to the webcast today at 11:30 AM ET to hear from our leadership: ow.ly/fVBu50Q3p74 $IONS